RGIN Stock Overview
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Regenicin, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.005 |
| 52 Week High | US$0.0054 |
| 52 Week Low | US$0.000001 |
| Beta | 9.48 |
| 1 Month Change | 4,900.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -70.41% |
| 5 Year Change | -58.68% |
| Change since IPO | -83.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGIN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how RGIN performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RGIN performed against the US Market.
Price Volatility
| RGIN volatility | |
|---|---|
| RGIN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGIN's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RGIN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3 | Randy McCoy | www.regenicin.com |
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures.
Regenicin, Inc. Fundamentals Summary
| RGIN fundamental statistics | |
|---|---|
| Market cap | US$767.42k |
| Earnings (TTM) | -US$985.39k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs RGIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGIN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$985.39k |
| Earnings | -US$985.39k |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0064 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -10.4% |
How did RGIN perform over the long term?
See historical performance and comparison